Cloud-Clone launches ADMA ELISA kit for endothelial dysfunction research

Cloud-Clone Corp. introduced an Asymmetric Dimethylarginine ELISA kit aimed at improving measurement accuracy for a biomarker tied to vascular, metabolic and kidney diseases. The company says the kit is designed to reduce degradation, cross-reactivity and matrix interference that can distort ADMA research results.

Why it matters: - Asymmetric dimethylarginine, or ADMA, is a key biomarker in research on endothelial dysfunction, cardiovascular disease, metabolic disorders and chronic kidney disease. - Accurate ADMA measurement is critical for animal studies, cell-based assays, drug screening and disease-risk research. - Common testing problems can produce low readings, false positives and weak signal differences, slowing research progress.

What happened: - Cloud-Clone Corp. introduced its Asymmetric Dimethylarginine (ADMA) ELISA Kit, Cat. No. CEB301Ge, for research use. - The company positioned the kit as a solution for the main analytical challenges in ADMA testing. - Cloud-Clone said the kit is intended for vascular biology, cardiovascular research, metabolism and nephrology studies.

The details: - ADMA is a methylated metabolite of arginine that inhibits endothelial nitric oxide synthase, lowering nitric oxide production and disrupting vascular balance. - Elevated ADMA is linked to endothelial injury and to progression in cardiovascular, metabolic and renal diseases. - ADMA is generated through protein arginine methylation by PRMTs and is mainly cleared by dimethylarginine dimethylaminohydrolase, or DDAH. - Impaired DDAH activity, increased PRMT activity or reduced renal function can raise ADMA levels. - ADMA is unstable in ambient conditions, with light exposure, room-temperature storage and repeated freeze-thaw cycles contributing to degradation. - Serum, plasma, cell culture supernatant, tissue homogenate and urine can all contain interfering molecules that complicate ADMA testing. - The kit uses a high-specificity antibody system intended to reduce cross-reactivity with SDMA, L-NMMA, L-arginine and other related metabolites. - The kit includes stabilization buffers designed to limit degradation during dilution, incubation and reaction steps. - The assay is designed for sensitivity across a broad linear range so it can detect small ADMA shifts in baseline, disease and treatment settings. - Cloud-Clone says the kit works with human, rat, mouse and rabbit samples. - The kit is compatible with serum, plasma, vascular or renal tissue homogenate, cell culture supernatant and urine. - Cloud-Clone says the assay can be completed in about three hours and uses a detachable 96-well plate format. - The reagents are pre-formulated and ready to use.

Between the lines: - The release highlights a common tradeoff in ADMA research: LC-MS/MS and HPLC offer strong analytical performance, but they are costly, slower and less practical for routine high-throughput studies. - Generic ELISA kits are presented as the more accessible option for basic research, but one that often struggles with stability, specificity and sensitivity. - Cloud-Clone is using that gap to position its kit as a lower-friction alternative for labs that need repeatable results without mass spectrometry infrastructure.

What's next: - Cloud-Clone says the kit is intended to support endothelial mechanism studies, cardiovascular disease models, metabolic complication research, chronic kidney disease work and vascular-protective drug screening. - The company said it will continue developing detection solutions for small-molecule metabolites and biomarkers. - Further product information is available through Cloud-Clone's website.

The bottom line: - Cloud-Clone is betting that a more stable and specific ADMA ELISA kit can make a difficult biomarker easier to measure in routine research workflows.